menu
    • menu
    [{"orgOrder":0,"company":"Spexis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Murepavadin","moa":"Imp protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Spexis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spexis \/ Inapplicable"},{"orgOrder":0,"company":"Polyphor","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Murepavadin","moa":"Imp protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Polyphor \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Polyphor \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Polyphor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Murepavadin","moa":"Imp protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Polyphor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Polyphor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Polyphor \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Murepavadin

    Menu

    Murepavadin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Spexis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Spexis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Murepavadin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Spexis Reports Solid Safety and Pharmacokinetics Results from First-In-Human Study with Inhaled Murepavadin, a...

                            Details : Inhaled Murepavadin is an antibiotic targeting pseudomonas aeruginosa in cystic fibrosis, non-CF bronchiectasis. It binds to LptD and inhibits lipopolysaccharide transport function of LptD and causes lipopolysaccharide alterations in the bacterium and ul...

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            September 01, 2023

                            Lead Product(s) : Murepavadin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Polyphor

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Polyphor

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Murepavadin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin

                            Details : The phase I study will evaluate the safety and tolerability of single and multiple ascending doses of inhaled murepavadin in healthy volunteers and will be jointly funded by Polyphor and the European Innovative Medicines Initiative (IMI).

                            Product Name : POL7080

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            December 22, 2020

                            Lead Product(s) : Murepavadin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Polyphor

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Polyphor

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Murepavadin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Cystic Fibrosis Foundation

                            Deal Size : $3.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            CF Foundation Awards Up to $3.3M to Polyphor for Inhaled Version of Antibiotic murepavadin to Treat Pseudomona...

                            Details : Award will help to fund planned Phase Ib/IIa study of inhaled murepavadin, a novel class antibiotic for the treatment of chronic Pseudomonas aeruginosa infections in cystic fibrosis.

                            Product Name : POL7080

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            November 24, 2020

                            Lead Product(s) : Murepavadin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Cystic Fibrosis Foundation

                            Deal Size : $3.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth